An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Tirzepatide, sold as Mounjaro, got a wider label and the company that makes it just raised how much money they expect to earn from it. In plain terms: regulators approved Mounjaro for more uses, and the drugmaker now thinks Mounjaro will bring in a lot more sales than they previously forecast — the new revenue outlook is roughly $85–$87 billion. Mounjaro (generic name tirzepatide) is a drug that acts like hormones your gut releases after you eat. Those hormones normally tell your brain you’re full and help control blood sugar. Mounjaro is a lab-made version that activates two of those hormone receptors, so it both reduces appetite and improves blood-sugar control. People hear it compared to Ozempic or Wegovy because those drugs do similar things, but Mounjaro targets one extra receptor, and that can make it more powerful for weight loss and diabetes in some studies. The news combines two things: a label expansion and an updated sales forecast. A “label expansion” means regulators approved Mounjaro for additional uses or patient groups beyond what it was originally cleared for. The revenue update — $85–$87 billion — is the company saying they now expect that much money from Mounjaro sales over a future period (the snippet doesn’t say exactly how long). The underlying research and prescribing evidence that motivated the expansion mostly come from clinical trials testing tirzepatide’s effects on weight and blood sugar. Those trials showed substantial weight loss and improved markers of diabetes compared with older drugs, but most large trials were controlled studies with specific patient groups, not broad real-world tests. The snippet doesn’t provide trial sizes or timing, so we can’t say exactly how many people or how long-term the data are. Why this matters: if Mounjaro is approved for more people, more doctors can prescribe it and more patients can potentially benefit. For people struggling with obesity or type 2 diabetes, that could mean access to a treatment that often reduces weight and improves blood sugar better than older options. For investors and the healthcare system, the huge revenue number signals both strong demand and major financial impact — that can affect drug prices, insurance coverage debates, and how much attention health systems pay to obesity and diabetes treatment. There are important caveats. Label expansion doesn’t mean the drug is right for everyone; safety, side effects, and long-term effects remain concerns. Common side effects for this class of drugs include nausea, stomach pain, diarrhea, and sometimes more serious digestive or metabolic issues. Long-term safety data are still accumulating. Also, a company revenue forecast is a business prediction, not a clinical result — it reflects expectations about demand, pricing, and approvals, and it can change. Finally, regulatory approval and insurance coverage vary by country, so availability and out-of-pocket cost will differ. Bottom line: Mounjaro’s official use is growing and the company expects huge sales, reflecting strong clinical results and demand, but individual benefits, safety, and access depend on real-world use, long-term data, and who pays for it.
Source: TradingView